Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 5;3(2):e181.
doi: 10.1097/HS9.0000000000000181. eCollection 2019 Apr.

The Landscape of KMT2A-PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical Outcome

Adil S A Al Hinai  1   2 , Marta Pratcorona  3 , Tim Grob  2 , François G Kavelaars  2 , Elena Bussaglia  3 , Mathijs A Sanders  2 , Josep Nomdedeu  3 , Peter J M Valk  2
Affiliations

The Landscape of KMT2A-PTD AML: Concurrent Mutations, Gene Expression Signatures, and Clinical Outcome

Adil S A Al Hinai et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors have indicated they have no potential conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Mutational landscape and gene expression changes of KMT2A-PTD AML. A) KMT2A-PTD mutation landscape. Each column represents an individual AML patient. The gene mutations are categorized according to gene function and family. The number and the percentage of the gene mutations in KMT2A-PTD AML and the AML reference cohort and p-value are indicated. B) The frequency of concurrent mutations of KMT2A-PTD AML (red) and the reference cohort (blue).
Figure 2
Figure 2
Overall survival analysis KMT2A-PTD AML and concurrent mutations. A) KMT2A-PTD with and without DNMT3A mutations (P = 0.0087). B) KMT2A-PTD with and without NRAS mutations (P < 0.0001).
See this image and copyright information in PMC

References

    1. Steudel C, Wermke M, Schaich M, et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer. 2003;37:237–251. - PubMed
    1. Basecke J, Whelan JT, Griesinger F, et al. The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol. 2006;135:438–449. - PubMed
    1. Shimada A, Taki T, Tabuchi K, et al. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group. Pediatr Blood Cancer. 2008;50:264–269. - PubMed
    1. Whitman SP, Liu S, Vukosavljevic T, et al. The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood. 2005;106:345–352. - PMC - PubMed
    1. Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002;10:1107–1117. - PubMed